T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2451
CarParts.com
PRTS
$50.3M
| $285K | ﹤0.01% |
4,100
+650
| +19% | +$47.4K |
|
|
SRNE
2452
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $285K | ﹤0.01% |
141,561
+10,846
| +8% | +$18.8K |
|
|
KNBE
2453
DELISTED
KnowBe4, Inc. Class A Common Stock
KNBE
| $285K | ﹤0.01% |
+18,250
| New | +$357K |
|
|
SRDX
2454
DELISTED
Surmodics
SRDX
| $284K | ﹤0.01% |
7,620
+80
| +1% | +$3.1K |
|
2455
Standex International
SXI
$3.97B
| $283K | ﹤0.01% |
3,342
+470
| +16% | +$44K |
|
2456
Talos Energy
TALO
$2.58B
| $283K | ﹤0.01% |
18,311
-1,698
| -8% | -$33K |
|
2457
Vanguard Morningstar Total Stock Market ETF
VTI
$696B
| $283K | ﹤0.01% |
1,500
| – | – |
|
2458
WisdomTree
WT
$3.44B
| $283K | ﹤0.01% |
55,756
+1,015
| +2% | +$5.82K |
|
2459
Mesa Laboratories
MLAB
$633M
| $282K | ﹤0.01% |
1,383
+34
| +3% | +$7.44K |
|
2460
Ocugen
OCGN
$458M
| $282K | ﹤0.01% |
124,022
-6,220
| -5% | -$14.9K |
|
2461
Columbus McKinnon
CMCO
$550M
| $281K | ﹤0.01% |
9,904
+265
| +3% | +$9.12K |
|
2462
Geron
GERN
$982M
| $281K | ﹤0.01% |
181,281
+6,941
| +4% | +$9.81K |
|
2463
Olema Pharmaceuticals
OLMA
$920M
| $279K | ﹤0.01% |
68,500
-2,372
| -3% | -$7.52K |
|
|
CDMO
2464
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $279K | ﹤0.01% |
18,289
+400
| +2% | +$5.92K |
|
2465
PUT
GameStop
GME
$8.33B
| $278K | ﹤0.01% |
36,400
-20,000
| -35% | -$636K |
|
|
BCOV
2466
DELISTED
Brightcove, Inc.
BCOV
| $278K | ﹤0.01% |
44,012
+126
| +0.3% | +$888 |
|
2467
Nuvation Bio
NUVB
$2.14B
| $276K | ﹤0.01% |
85,107
+34,653
| +69% | +$151K |
|
2468
Brookfield Renewable
BEPC
$6.66B
| $275K | ﹤0.01% |
7,709
+248
| +3% | +$9.17K |
|
2469
Liberty Latin America Class A
LILA
$1.67B
| $273K | ﹤0.01% |
51,507
+230
| +0.4% | +$1.43K |
|
2470
Unisys
UIS
$210M
| $271K | ﹤0.01% |
22,494
+454
| +2% | +$6.4K |
|
2471
American Well
AMWL
$220M
| $270K | ﹤0.01% |
3,119
+1,271
| +69% | +$94.8K |
|
|
ICPT
2472
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $270K | ﹤0.01% |
19,524
-1,367
| -7% | -$21.9K |
|
|
BTRS
2473
DELISTED
BTRS Holdings Inc. Class 1 Common Stock
BTRS
| $269K | ﹤0.01% |
53,916
+2,836
| +6% | +$16.3K |
|
2474
DHI Group
DHX
$174M
| $268K | ﹤0.01% |
+53,851
| New | +$320K |
|
|
QUOT
2475
DELISTED
Quotient Technology Inc
QUOT
| $268K | ﹤0.01% |
90,198
+500
| +0.6% | +$2.37K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.